Navigation Links
Promise for Soya Allergy Sufferers

Two Chinese soybean lines that grow without the primary protein linked to soy allergies in children and adults have been isolated by scientists//.

The two lines already are adapted to Illinois-like conditions and will be given away to breeders seeking to produce new varieties of allergy-free soybeans without genetic engineering.

Crop scientists at the University of Illinois at Urbana-Champaign and the USDA-Agricultural Research Service's Donald Danforth Plant Science Center in St. Louis screened more than 16,000 soybean lines kept in the USDA's National Soybean Germplasm Collection. The findings will appear later this year in the journal Crop Science.

The two soybean lines (PI 567476 and PI 603570A) contain virtually identical genetic mutations that do not contain the leading allergy-causing P34 protein, which consists of 379 amino acids, said Theodore Hymowitz, emeritus professor of plant genetics in the crop sciences department at the U. of I.

‘We are releasing this information with no patents so that companies and breeders involved with soybeans can incorporate these two lines as quickly as possible,’ Hymowitz said. Companies in Japan, Canada and across the United States have been following the research effort, he added.

The research, which was funded primarily by the Illinois-Missouri Biotechnology Alliance, went through two stages.

First, using a specially developed immunochemistry approach, Hymowitz's post-doctoral assistant Leina M. Joseph examined 100 lines of soybeans per day for nine months from the UI-based collection. Seeds were crushed, treated and placed on a membrane for screening. A second screening using stronger antibodies and protein gels was done to confirm the absence of P34 in the two domestic lines, Joseph said.

After the two lines were isolated, seeds were sent to the Danforth Center for additional molecular analysis to determine why P34 was absent. Six ident ical genetic mutations were found in each, indicating the two lines may be related, Hymowitz said.

‘The lack of the protein was confirmed by more-detailed two-dimensional protein assays,’ said Eliot M. Herman, a lead scientist at Danforth who probed the seeds with post-doctoral researcher Monica A. Schmidt. ‘We then isolated the gene responsible for the lesion, and we found there was a single significant change in the gene's sequence that likely produced a protein which could not be made as a stable product.’

Herman discovered P34 in the early 1990s and in 2003 had successfully used a gene-silencing technique to create a soybean line in which P34 was ‘knocked out.’ However, because of public resistance to genetically modified products researchers have been seeking a more traditional approach. Because the newly identified lines occur naturally, they can be successfully crossed into other soybean lines ‘without any biotechnology-derived component,’ the researchers noted.

‘Soybeans are slowly but surely increasingly being used in the foods we eat, and with that we are noticing an increase in the number of children and adults that have allergies to soybeans,’ Hymowitz said.

Currently, 6 percent to 8 percent of children are allergic to soy-based products, including infant formulas, while 2 percent of adults have had allergic reactions, which range from harmless skin reactions and gastrointestinal irritation to more serious facial swelling, shortness of breath, difficulty swallowing and fainting.

Avoiding soy products is becoming more difficult because of soy's use as fillers and components of many menu items. While people can read labels before preparing meals at home, avoiding soy at restaurants isn't as easy, Hymowitz said.

'"/>




Related medicine news :

1. New Prostate Cancer Vaccine Shows Promise
2. Ebola Treatment Shows Promise
3. Stem Cells Found To Offer Promise For Hair Growth
4. Promised Drug Doesnt Help Acute Heart Failure
5. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
6. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
7. New Pancreatic Cancer Vaccine Holds Promise
8. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
9. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
10. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
11. Cervical Cancer Vaccine Show Promise In Prevention
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: